NanoViricides starts Phase II DRC trial of oral NV-387 gummies in Bundibugyo Ebola patients
Bitget2026/09/28 12:45- NanoViricides began enrolling and dosing patients in a Phase II trial of NV-387 oral gummies for Ebola in the Democratic Republic of Congo.
- No results have been presented; the study is designed to generate safety, tolerability, and effectiveness data in a later randomized phase.
- The initial dose run-in aims to set a tolerable dosing approach for sicker patients before moving into the efficacy evaluation.
- The program targets Bundibugyo ebolavirus, positioning NV-387 as a potential oral alternative to infusion-based treatments under evaluation.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Only twice in history! S&P 500 equal-weight index is expected to record seven consecutive weeks of decline this week
The S&P 500 Equal Weight Index is expected to fall for a seventh consecutive week. If this downward trend continues through Friday, it will mark only the third time in history that the index has experienced seven straight weeks of decline.
Trump “bites” Powell, demanding his resignation from the Federal Reserve Board, citing severe cost overruns in headquarters renovation.
U.S. President Trump on Wednesday called for former Federal Reserve Chairman Powell to resign from his position as a Fed governor, following an inspector general report on the Federal Reserve headquarters renovation project, which highlighted a series of management issues that led to significant cost overruns.
Gladstone Investment Closes Acquisition of Extrude Hone
Crypto prices
More
